Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37205789)
Watch
English
Sorafenib in the management of metastatic renal cell carcinoma
scientific article published on May 2009
In more languages
default values for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
title
Sorafenib in the management of metastatic renal cell carcinoma
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
main subject
renal cell carcinoma
1 reference
based on heuristic
inferred from title
metastatic renal cell carcinoma
1 reference
based on heuristic
inferred from title
author name string
C Guevremont
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
C Jeldres
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
P Perrotte
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
P I Karakiewicz
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
publication date
1 May 2009
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
published in
Current Oncology
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
volume
16 Suppl 1
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
page(s)
S27-32
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
copyright license
Creative Commons Attribution 4.0 International
start time
1 May 2009
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Sorafenib in advanced clear-cell renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
6 September 2017
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
14 September 2017
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
14 September 2017
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
14 September 2017
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
3 September 2018
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
3 September 2018
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
3 September 2018
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687798
retrieved
3 September 2018
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/19478894
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.3747/CO.V16I0.430
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PMC publication ID
2687798
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
PubMed publication ID
19478894
1 reference
stated in
Europe PubMed Central
PMC publication ID
2687798
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19478894%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit